Product Search

#10326 Anti-Human Amyloidβ (N) (82E1) Mouse IgG MoAb Biotin

Intended Use：
Research reagents
Application：
WB, IP, IHC
Package Size1：
50 μg
Package Size2：
5 μg
Note on Application Abbreviations
WB:Western Blotting
IP:Immunoprecipitation
IHC:Immunohistochemistry

※ The product indicated as "Research reagents" in the column Intended Use cannot be used
　 for diagnostic nor any medical purpose.
※ The datasheet listed on this page is sample only. Please refer to the datasheet
　 enclosed in the product purchased before use.

Product Overview

Product Overview

Product Code 10326
Product Name Anti-Human Amyloidβ (N) (82E1) Mouse IgG MoAb Biotin
Intended Use Research reagents
Application WB, IP, IHC
Species Human
Immunizing antigen Synthetic peptide for Human Amyloid (1-16) (DAEFRHDSGYEVHHQK)
Source Mouse-Mouse hybridoma　(X63-Ag8.653×BALB/c mouse spleen cells)
Clone Name 82E1
Subclass IgG1
Purification Method Affinity purified with antigen peptide
Specificity Human Aβ and β-CTF N-terminal specific.
Reacts with both soluble and fibrillar Aβ in a similar degree.
Not react with non-cleaved APP.
Package Form Lyophilized product from PBS containing 1% BSA and 0.05 % NaN3
Storage Condition 2 - 8℃
Poisonous and Deleterious Substances Applicable
Cartagena Not Applicable
Package Size 1 50 μg
Package Size 2 5 μg
Remarks1 The commercial use of products without our permission is prohibited. Please make sure to contact us and obtain permission.

Product Description

Product Description

Alzheimer's disease (AD) is characterized by the presence of extracellular plaques and intracellular neurofibrillary tangles (NFTs) in the brain. The major protein component of these plaques is beta amyloid (Aβ) peptide, a 40 to 43 amino acid peptide cleaved from amyloid precursor protein by β-secretase and γ-secretase. Increased release of Aβ42 or Aβ43, both of which exibit a greater tendency to aggregate than Aβ40, occurs in individuals expressing certain genetic mutations, ApoE alleles or may involve other undiscovered factors. Many researchers theorize that it is this increased release of Aβ42/Aβ43 which leads to the abnormal deposition of Aβ and the associated neurotoxicity in the brains of affected individuals. It is also reported that a distinct Aβpeptide, AβN3pE, is deposited in senile plaques in a dominant and differential manner as compared with the standard Aβpeptide.

FAQ

FAQ

  • Question
    Q.Does this antibody react to any APP isoform?
  • Answer
    A.As the antibody specifically reacts N-terminal of Amyloidβ, it does not react to APP, Aβ(2-40) and Aβ(3-40).
  • Question
    Q.How do you biotinylation the antibody?
  • Answer
    A.NHS-LC-Biotin is used for the biotinylation.

Related Products

Related Products

Contact Us >